 |
|
|
|
|
|
|
At the conclusion of this symposium, participants should be able to:
- Describe the anatomic and electrophysiologic substrate for VT in various disease
states such as in patients with a history of myocardial infarction, dilated cardiomyopathy,
hypertrophic cardiomyopathy, or arrhythmogenic right ventricular cardiomyopathy
- Describe the mechanisms underlying the various ventricular arrhythmias including
monomorphic ventricular tachycardia, polymorphic ventricular tachycardia
and ventricular fibrillation
- Discuss the role of the autonomic nervous system in ventricular arrhythmogenesis
- Describe the role of animal models for mimicking the pathophysiology of VT in man
- Describe the role of fibrosis in promoting and preventing ventricular arrhythmias
- Explain the current status and future role for implantable cardioverter-defibrillators
in the management of sudden cardiac death
- Discuss advances in cardioverter-defibrillator technology as it relates to VT localization
- Describe optimum ICD programming to decrease ICD shocks
- Identify the techniques and limitations of performing activation and entrainment
mapping of hemodynamically stable ventricular tachycardia in post-MI patients
- Identify new ablation energy sources and catheter designs for performing ablation
of ventricular tissue
- Describe strategies for improving the value of pacemapping/template mapping
- Describe the status of ongoing multicenter VT trials and discuss which questions
need to be answered by trials in the future
- Discuss the techniques and pitfalls in ablating VT originating from the aortic sinuses
- Describe the techniques employed in the ECG localization and catheter ablation of
epicardial VT
- Explain the safety and efficacy of pericardial access, catheter mapping and ablation of
epicardial ventricular tachycardia
- Discuss the incidence and possible mechanisms of PVC-associated cardiomyopathy
- Describe the ECG signature and techniques for ablating VT arising from the
papillary muscle region
- Identify risk stratification strategies for sudden cardiac death and VT/VF
|
|
|
|
|